Anti-Prekallikrein Heavy Chain Antibody (19901)

$635.00

Host Quantity Applications Species Reactivity Data Sheet  
Mouse 200ug WB,ELISA Human
SKU: 19901 Categories: , ,
Overview
Product Name Anti-Prekallikrein Heavy Chain Antibody (19901)
Description Anti-Prekallikrein Heavy Chain Mouse Monoclonal Antibody
Target Prekallikrein Heavy Chain
Species Reactivity Human
Applications WB,ELISA
Host Mouse
Clonality Monoclonal
Clone ID 13G11
Isotype IgG1
Immunogen Purified human prekallikrein.
Properties
Form Liquid
Concentration Lot Specific
Formulation PBS, pH 7.4.
Buffer Formulation Phosphate Buffered Saline
Buffer pH pH 7.4
Format Purified
Purification Purified by Protein G affinity chromatography
Specificity Information
Specificity This antibody recognizes two variants of prekallikrein in human plasma, 88kDa and 85kDa, and its activation products kallikrein, the complexes formed by kallikrein with its endogenous inhibitors C1 inhibitor, alpha-2-macroglobulin and antithrombin III, and 45kDa prekallikrein/kallikrein fragments. It also recognizes prekallikrein and its activation products in chimpanzee, rhesus, and baboon plasmas. The epitope for this antibody is located on the prekallikrein/kallikrein hevy chain and is involved in the interaction between prekallikrein and factor XIIa. This antibody inhibits prekallikrein activation in human and rhesus plasmas by ~60- 80% and 55%, respectively. This antibody does not cross-react with tissue kallikrein.
Target Name Plasma kallikrein
Target ID Prekallikrein Heavy Chain
Uniprot ID P03952
Alternative Names EC 3.4.21.34, Fletcher factor, Kininogenin, Plasma prekallikrein, PKK [Cleaved into: Plasma kallikrein heavy chain; Plasma kallikrein light chain]
Gene Name KLKB1
Sequence Location Secreted.
Biological Function The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.
Research Areas Coagulation factors.
Background Human prekallikrein, a serine protease zymogen, is present in plasma as two variants, 88kDa and 85kDa, probably due to different carbohydrate content. Approximately 75% of the total prekallikrein in plasma is noncovalently associated with high molecular weight kininogen (HMWK). HMWK mediates binding of prekallikrein to a negatively-charged surface which is required for its optimal activation to kallikrein by activated factor XII. Although kallikrein light and heavy chains can behave as functionally independent domains, the interaction between these two chains is essential for full biologic activity.
Application Images
Description Immunoblotting: use at 1-5ug/ml. Bands of 85kDa and 88kDa are detected. Detection of prekallikrein in normal human plasma (Lanes 2 and 3). For comparison, purified human prekallikrein is included in Lane 1.
Description Western blot validation of the three differentially expressed proteins identified by the iTRAQ-based proteomics approach were performed using the remaining five plasma samples from each of the groups. Significant differences among multiple groups were calculated by one-way analysis of variance (ANOVA) followed by Tukey’s Honest Significant Difference test. * means p < 0.05 between the control group and 1 day or 3 day group.
Additional Information
Handling
Storage This antibody is stable for at least one (1) year at -20°C.
Dilution Instructions Dilute in PBS or medium that is identical to that used in the assay system.
Application Instructions Immunoblotting: use at 1-5ug/mL. Bands of 85kDa and 88kDa are detected

ELISA: use at 5-10ug/mL with prekallikrein sample bound to ELISA plates.

These are recommended concentrations.

Endusers should determine optimal concentrations for their applications.
References & Data Sheet
References Das A et al. Evidence for binding of the ectodomain of amyloid precursor protein 695 and activated high molecular weight kininogen. Biochim Biophys Acta 1571: 225-38 (2002).
Campbell DJ et al. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans Am J Physiol Integrative Comp Physiol 281: R1059-70 (2001).
Veloso D Does resistance to endotoxin in primates correlate with levels of plasma prekallikrein? Immunopharmacology 33: 374-6 (1996).
Veloso D et al. Structure, kinetics, and function of human and rhesus plasma prekallikreins are similar. Thrombosis and Haemostatis 68: 526-533 (1992).
Veloso D and Colman RW Western blot analyses of prekallikrein and its activation products in human plasma. Thrombosis and Haemostatis 65: 382-8°C8 (1991).
Veloso D et al. Binding of a monoclonal anti-human plasma prekallikrein antibody to the complexes of kallikrein with C1-inhibitor and alpha 2-macroglobulin analyzed by immunoblot and “sandwich†assays. Adv Exp Med Biol 247: 499-505 (1989).
Veloso D et al. A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface. Blood 70: 1053-62 (1987).
Integrated Proteomics and Metabolomic Analyses of Plasma Injury Biomarkers in a Serious Brain Trauma Model in Rats. Int J Mol Sci (2019) [30791599]